【摘要】 目的：研究含安维汀的联合化疗方案在晚期难治性实体瘤中的疗效及安全性。方法：2011年10月-2012年9月，53例晚期实体肿瘤患者接受安维汀联合化疗方案治疗。安维汀用法为7.5 mg/kg静滴，d1；依据肿瘤类型和既往治疗史选择化疗方案。所有方案均以3周为一周期。结果：53例晚期实体肿瘤患者随访1～12个月，在50例可评价病例中，PR23例、SD18例、PD9例，有效率为46.0%，疾病控制率为82.0%；中位无疾病进展时间：031-034
【Abstract】 Objective：To determine the safety and efficacy of bevacizumab in combination with different chemotherapy regimens for second-line and second-line above treatment of refractory advanced solid tumors. Method：From October 2011 to september 2012， fifty three patients were eolled. The dose of bevacizumab was 7.5 mg/kg ，iv drip，d1. The chemotherapy regimens were chosen depending on the type of tumor and the past medical history. All the plans with 3 weeks for a cycle. Result： 53 patients with advanced solid tumors were followed up for 1 - 12 months， 50 cases could be evaluated： PR were 23 cases， SD were 18 cases， PD were 9 cases， the effective rate was 46.0%， the disease control rates was 82.0%； PFS was 5.4 months .The common adverse reaction were： the bone marrow suppression， fatigue， diarrhea and abdominal pain， hypertension， etc.； 3 - 4 adverse reaction were： neutropenia 16.0% ， the most common for pneumonia and abdominal pain， SVT were 4.0% respectively. Conclusion： Bevacizumab in combination with different chemotherapy regimen in treatment for late refractory solid tumors is safe and effective.
【Key words】 Bevacizumab； Refractory advanced solid tumors； Chemotherapy； Anti-angiogenesis
First-author’s address： The First People’s Hospital Affiliated Guangzhou Medical University，Guangzhou ，China
doi：10.3969/j.issn.1674-4985.2014.12.011
贝伐珠单抗： 724-730.
[12]朱春荣，熊峰，朱彦博，等.贝伐单抗联合FOLFOX4或FOLFIRI方案治疗晚期结直肠癌的临床观察[J].江苏医药，2012，38（19）：2306-2307.
[13] Gressett S M， Shah S R. Intricacies of bevacizumab-induced toxicities and their management[J]. Ann Pharmacother， 2009， 43（3）： 490-501.
（收稿日期：2014-02-12） （本文编辑：黄新珍）
查看全文
false